KKR: EU approves Sylvan Int. Biotech. transaction
(CercleFinance.com) - The European Commission has approved the acquisition of joint control of Sylvan International Biotechnology, of China, by Novo Nordisk Foundation, of Denmark, and KKR, of the US.
The transaction mainly concerns the market for the development and production of edible mushroom mycelium.
The Commission concluded that the notified transaction would not give rise to competition concerns, given that the joint venture has negligible activities in the European Economic Area and that the combined market position of the companies resulting from the proposed transaction is limited.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The transaction mainly concerns the market for the development and production of edible mushroom mycelium.
The Commission concluded that the notified transaction would not give rise to competition concerns, given that the joint venture has negligible activities in the European Economic Area and that the combined market position of the companies resulting from the proposed transaction is limited.
Copyright (c) 2024 CercleFinance.com. All rights reserved.